狼疮中糖皮质激素使用问题依然存在
该综述指出SLE治疗因缺乏安全有效的靶向治疗而复杂,医生也缺乏现有药物(包括糖皮质激素)的循证使用方法。新兴文献提示糖皮质激素使用本身除库欣样副作用外还导致SLE不良结局,呼吁重新评估长期使用并减少暴露以改善远期预后。
要点
- 糖皮质激素在SLE患者中广泛使用,但缺乏循证使用方法。
- 新兴文献提示糖皮质激素使用本身导致SLE不良结局。
- 应重新评估长期使用,将减少糖皮质激素暴露作为改善预后的策略。
核心结论
- 需要重新评估SLE中长期使用糖皮质激素,重点是最小化糖皮质激素暴露以改善长期结局。
研究设计与样本
- 综述,回顾糖皮质激素在SLE中有害效应的证据并提出减少依赖的治疗选择。
主要发现
- 新兴文献提示糖皮质激素使用本身导致SLE不良结局,超出库欣样副作用。
临床怎么用
- 提出减少依赖糖皮质激素的治疗选择,呼吁狼疮学界更深入讨论糖皮质激素使用并摒弃对其风险获益比的残余自满。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The treatment of SLE remains complex, and management is constrained by a lack of safe, effective, targeted therapies. Physicians, also, are constrained by a lack of evidence-based approaches with existing agents, including glucocorticoids, utilized in the majority of patients. While Cushingoid side effects of glucocorticoids are widely recognized, emerging literature now suggests that glucocorticoid use actually contributes to harmful outcomes in SLE, over and above these effects. These studies provide a compelling case for a re-evaluation of the long-term use of glucocorticoids in SLE, focusing on minimizing glucocorticoid exposure as part of the strategy to improve long-term outcomes. In this article, we review the evidence for the harmful effects of glucocorticoids in SLE, and propose therapeutic options that reduce reliance on glucocorticoids. We propose that it is time for the lupus community to have a louder conversation about glucocorticoid use, and for any residual complacency about their risk-benefit ratio to be banished.
引用
- Apostolopoulos D, Morand EF. It hasn't gone away: the problem of glucocorticoid use in lupus remains. Rheumatology (Oxford). 2017. PMID: 28013208. doi:10.1093/rheumatology/kew406
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。